

SPECIALTY GUIDELINE MANAGEMENT

Doxil (doxorubicin liposomal)

Subject: Doxil ® (doxorubicin liposomal)

Overview: Doxil is an anti-cancer chemotherapy drug. It is used to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors.

Policy: HPHC covers the use of Doxil for members with the following condition(s):

- AIDS-related Kaposi sarcoma (KS)
- Multiple myeloma
- Ovarian cancer
- Breast Cancer
- Soft Tissue Sarcoma
- Non Hodgkins Lymphoma – Mycosis Fungoides, Diffuse Large B-cell Lymphoma, Non-gastric MALT lymphoma, Primary cutaneous B-cell lymphoma
- Non Hodgkin Lymphoma: AIDS-related B-cell lymphoma
- Hodgkins Lymphoma
- Uterine Sarcoma
- Dermatofibrosarcoma Protuberans (DFSP)

HPHC does not cover the use of Doxil in the treatment of diagnoses or in dosages and frequencies other than those listed below.

Criteria: The use of Doxil is considered medically necessary when used in the treatment of the following condition(s):

FDA Approved Indications

Indications
AIDS-related Kaposi sarcoma (KS)
Multiple myeloma
Ovarian cancer

Compendia Listed Indications

Indications
Breast Cancer
Soft Tissue Sarcoma
Non Hodgkins Lymphoma – Mycosis Fungoides, Diffuse Large B-cell Lymphoma, Nongastric MALT lymphoma, Primary cutaneous B-cell lymphoma
Non Hodgkin Lymphoma: AIDS-related B-cell lymphoma
Hodgkins Lymphoma
Uterine Sarcoma
Dermatofibrosarcoma Protuberans (DFSP)

Dosage and Frequency

AIDS-related Kaposi sarcoma (KS): 20 mg/m²/dose once every 3 weeks
 Multiple myeloma/ NHL-Mycosis Fungoides: 30 mg/m²/dose every 3 weeks (on day 4)
 Ovarian cancer/Uterine Sarcoma/DFSP: 50 mg/m²/dose every 4 weeks



Breast Cancer: 45-50 mg/m² every 4 weeks
Hodgkin Lymphoma: 15mg/m²/dose days 1 and 8 every 21 days

Loading Dose
(No)

Max Units (per dose)
12 units

Rationale for Max Units

Assumptions:

Wt = 115kg, BSA = 2.5m²

$$50\text{mg}/\text{m}^2 \times 2.5\text{m}^2 = 125\text{mg} = 12 \text{ units}$$

Rounded to nearest vial size

Billing Unit: 10 mg

Exclusions: HPHC does not cover the use of Doxil for the treatment of diagnoses or in dosages and frequencies other than those listed above.

References:

1. Facts & Comparisons 4.0
2. Doxil package insert
3. NCCN Compendium
4. Clinical Pharmacology
5. Sutton G., et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2005 Mar;96(3):749-52